DeepC Enterprise: Built for the regulated enterprise

Sixteen specialist agents grounded in FDA, EMA, ICH, USP, and your own SOPs. Every claim cited to its primary record. Every action audit-logged.

CHECK 01PhysicsBond geometrysolubilityCHECK 02FrameworkICH · EMA · USPCHECK 03EvidenceKlimisch · multi-sourceTHE ANCHORReality AnchorPhysics · FrameworkEvidenceREJECTED · KS 350 mg/kg/dayNOAEL · NTP TR-403CITED · KS 1150 mg/kg/dayNOAEL · ECHA IUCLID

Five layers. One co-scientist.

From the chat surface your scientists use down to the compute running inference, DeepC works as one auditable system, every layer designed to leave a verifiable trail.

Chat workspaceChatworkspaceSixteen specialist agentsSixteenspecialistagentsReality Anchor reasoningRealityAnchorreasoningKnowledge graph & citationsKnowledgegraph &citationsFoundational computeFoundationalcompute
  • Chat workspaceMission Control
    Audit · Roles · Provenance · 7-year retention
  • Sixteen specialist agentsFor Formulation
    ICH Q8(R2) / CTD §3.2.P.2
  • Reality Anchor reasoningFor Safety Assessment
    ERA · E&L · Nitrosamines · OEL · PDE
  • Knowledge graph & citationsFor Regulatory Filing
    submission-ready PDFs
  • Foundational computeFor Custom Agents
    fine-tune on your SOPs

Built for what an R&D org actually does.

F-01RealityAnchorrefutationEvery output checkedbefore it ships.F-0221 CFR Part11 audit logEvery prompt logged.Hash-chained.F-03Custom agentson your SOPsTenant-scopedfine-tunes,versioned.F-04Per-agentcostattributionCFOs see whatscientists spend.F-05Klimisch-gradedcitationsEvery toxicologyclaim ranked 1 to 4.F-06Passkey +SCIM SSOWebAuthn, Okta, AzureAD, Ping.F-07Scoped roles& approvalsDual-signature gatesfor regulatoryexports.F-08Submission-readyPDFsICH M7, Q3E, EMARev.1, ECETOC TR 101.F-0999.9% SLA,multi-regionIndependentautoscaling,PDUFA-ready.

What your scientists actually ship.

Submission-ready dossiers, ranked safety evidence, candidate formulations, pulled straight out of DeepC, anchored to citable sources, ready for your QA and ready for your regulator.

Per ICH Q3E + USP <1664> + PQRI PODPCase file lea-7421-A
LEACHABLES ASSESSMENT

Lacosamide 10 mg/mL solution for infusion

SponsorAcme Pharmaceuticals plc
Prepared2026-04-22
Sign-off (left blank for Qualified Person)
Name
Signed
Date
Fig. 1 · Leachables assessmentView the full dossier
Cited studiesKlimisch reliability
  • Ks 1

    ECHA IUCLID Dossier 100.005.235

    NOAEL (rat, 90-day oral) · ECHA REACH

    GLP-compliant 90-day oral gavage study in Sprague-Dawley rats (5/sex/dose) at 0, 50, 150, 500 mg/kg/day. NOAEL of 150 mg/kg/day established; LOAEL of 500 mg/kg/day driven by hepatic centrilobular hypertrophy.

  • Ks 2

    EFSA peer-reviewed re-evaluation (2023)

    NOAEL (rat, 90-day oral) · EFSA

    Authoritative re-evaluation citing the underlying ECHA dossier. Concurs with NOAEL of 150 mg/kg/day for the same critical effect.

  • Ks 2

    Mortelmans et al. PMID 3781131

    NOAEL (rat, 90-day oral) · PubMed

    Peer-reviewed primary publication of the same 90-day oral toxicity study program. Methodology documented in detail; conclusions match the ECHA dossier.

  • Ks 3

    NTP TR-403 (secondary citation, trade publication 2019)

    NOAEL (rat, 90-day oral) · Industry whitepaper

    Reports a NOAEL of 50 mg/kg/day citing NTP TR-403. The cited NTP study uses a different strain (F344, not Sprague-Dawley) and a different route (drinking water, not gavage).

    Rejected by Reality Anchor: Strain and route mismatch; superseded by Ks 1 ECHA dossier.

Fig. 2 · Klimisch-ranked evidenceHow Reality Anchor ranks
F02Oral, modified-release tablet
Recommended

MR Matrix (HPMC K100M)

Composition
ExcipientFunction% w/w
ActiveAPI35
HPMC K100MHydrophilic matrix former30
Lactose monohydrateFiller25
Microcrystalline celluloseFiller / binder8.5
Magnesium stearateLubricant1
Colloidal silicon dioxideGlidant0.5
BCS classII
Target Tmax6-8 h
Target stability24 mo at 25°C / 60% RH
ManufacturingDirect compression
IID precedentNDA 022030Mirapex ER 0.375 mg
Rationale

HPMC K100M selected as the primary release-control matrix at 30% w/w; concentration sits within IID precedent for oral MR products on Mirapex ER (NDA 022030). Lactose monohydrate and MCC chosen for direct-compression compatibility and to stabilise the API in a low-water-activity matrix.

Fig. 3 · Candidate formulationSee the Formulation Agent
AUDIT TRAIL · 21 CFR 112026-05-0814:32alicerun formulation_agent14:31bobapprove safety_report14:30aliceupload SOP_2024.pdf14:28carolexport ERA_lacosamide.pdf14:25bobassign role=EditorHASH 0x9c37…a4f1 · CHAIN VERIFIEDOwnerEditorViewer7-year retention · tamper-evident hash chain
01

Compliance & Governance

Every action you'd report in an audit, already logged. DeepC records every prompt, agent invocation, retrieval call, document upload, regulatory PDF export, and role change with a tamper-evident hash chain. Audit logs stream to your SIEM in real time and are retained for seven years to meet 21 CFR Part 11 and GxP requirements. Mission Control gives compliance teams scoped read-only access to the entire trace.

  • 21 CFR Part 11 electronic records & signatures
  • GxP-aligned SDLC and change control
  • Klimisch reliability tiers on every cited toxicology study
  • 7-year audit retention
  • Tamper-evident log hash chain
21 CFR Part 11GxPICH Q9EU GDPRHIPAA-ready
02

Reliability & Scale

Built for production research workloads. The chat surface, the analytics sandbox, and the regulatory PDF compiler each run on independently autoscaled fleets. We target 99.9% uptime under SLA, with multi-region failover for organizations filing in multiple jurisdictions simultaneously.

  • 99.9% uptime SLA target
  • Multi-region failover
  • Independent autoscaling for chat, sandbox, and PDF compile
  • Capacity planning during regulatory crunch (PDUFA, MAA submission windows)
  • Status page + dedicated Slack support channel
0.9%
Uptime SLA target
0
Regions available (EU · US · UK · SG)
0 yrs
Audit log retention

Mission control, as you'll actually use it.

These three views are lifted directly from the deployed enterprise admin console: what your admins and compliance officers see when they log in.

01

Overview

Month-to-date spend, seat usage, agent-call volume, top agents, and the live activity feed, the first thing your org admins see when they log in.

Northstar Therapeutics

Overview

Welcome back, Marisol Adeyemi

View billing
Add User
Month to Date
Bill
$2,184.63
Users
12 of 50
Seats used
DeepC Calls
4,283
Across all agents

Top Agents

Orchestrator
$612.1830%
Formulation Agent
$487.9424%
Research Agent
$396.2720%
Optimization Agent
$314.5516%
Analytics Agent
$198.4110%

Recent Activity

View all audit log
  • DATA

    Toxicology dossier exported

    sarah.chen@northstar.bio · NX-204 PDE assessment v3.pdf

    14m ago
  • SYSTEM

    Invoice generated

    System · INV-2026-05-NORTH

    2h ago
  • RESEARCH

    Formulation report signed

    rajesh.k@northstar.bio · NX-204 ASD formulation v7

    5h ago
  • SYSTEM

    User role changed to Org Admin

    admin@northstar.bio · lena.fischer@northstar.bio

    yesterday
  • DATA

    API specification uploaded

    tomo.h@northstar.bio · NX-117 drug substance specs.xlsx

    yesterday
  • AUTH

    Passkey enrolled

    priya.r@northstar.bio · YubiKey 5C NFC

    2 days ago
02

Audit Log

Every prompt, document export, role change, and signature recorded with category, actor, resource, and status. 21 CFR Part 11 retention. Filterable. GxP-tagged.

Audit Log

Activity history for your organization. Useful for compliance and security review.

Category:AllAuthDataSystemSecurityResearch
Range:Last 24 hoursLast 7 daysLast 30 daysAll time
Showing 12 of 247 events
WhenActionActorResourceStatus
14m ago
DATA GxP
Toxicology dossier exported
sarah.chen@northstar.bio
User
Document
NX-204 PDE assessment v3.pdf
2h ago
SYSTEM
Invoice generated
System
Invoice
INV-2026-05-NORTH
5h ago
RESEARCH GxP
Formulation report signed
rajesh.k@northstar.bio
User
Report
NX-204 ASD formulation v7
yesterday
SYSTEM
User role changed
admin@northstar.bio
Org Admin
User
lena.fischer@northstar.bio
yesterday
DATA GxP
API specification uploaded
tomo.h@northstar.bio
User
Document
NX-117 drug substance specs.xlsx
2 days ago
AUTH
Passkey enrolled
priya.r@northstar.bio
User
Passkey
YubiKey 5C NFC
2 days ago
RESEARCH GxP
PDE assessment generated
sarah.chen@northstar.bio
User
Assessment
NX-204 nitrosamine PDE
3 days ago
SECURITY
Login failed (invalid passkey)
compliance@northstar.bio
Read-only
Session
3 days ago
SYSTEM
Seat cap increased
admin@northstar.bio
Org Admin
Organization
25 → 50 seats
4 days ago
DATA GxP
SOP document ingested
rajesh.k@northstar.bio
User
Document
SOP-2026-018 ASD platform.docx
4 days ago
SYSTEM
User invited
admin@northstar.bio
Org Admin
User
eli.rosenberg@northstar.bio
5 days ago
RESEARCH GxP
Citation rebuild triggered
System
Knowledge graph
tox-corpus-v18
Load more (235 remaining)
03

Users

Seat-scoped role assignment with passkey-first auth. Org Admins, Admins, Users, and Read-only auditors, all SCIM-provisionable from your IdP.

Users

Manage users in your organization

Add User
Status:AllActiveInactive
Role:AllAdminOrg AdminUserRead-only
UserRoleStatusLast login
Marisol Adeyemi
admin@northstar.bio
Org Admin
Active
4m ago
Sarah Chen
sarah.chen@northstar.bio
User
Active
14m ago
Rajesh Kulkarni
rajesh.k@northstar.bio
User
Active
1h ago
Lena Fischer
lena.fischer@northstar.bio
Org Admin
Active
3h ago
Tomo Hashimoto
tomo.h@northstar.bio
User
Active
yesterday
Priya Ramaswamy
priya.r@northstar.bio
User
Active
2 days ago
Eli Rosenberg
compliance@northstar.bio
Read-only
Active
3 days ago
Jordan Lee
jordan.lee@northstar.bio
User
Inactive
21 days ago

Book a demo.

Tell us what you are working on (molecule, indication, stage, open question).

A formulation lead will be in touch within a business day.

By submitting, you agree to our Privacy Policy.